The Antimicrobial Resistance (AMR) – One Health Consortium is a pan-Alberta collaborative platform focused on antimicrobial use and resistance research, innovation, policy, training, outreach, and commercialization. The AMR – One Health Consortium uses a transdisciplinary, multisectoral One Health approach to promote self-sustaining clinical, epidemiologic, basic and social sciences, and translational research on AMR in Alberta that will be scalable to all of Canada and beyond. Our research focuses on treatment optimization, AMR surveillance and prevention of transmission. These projects span across 3 thematic areas: Innovation and Commercialization, Education and Societal Impact, and Policy, Economics and Sustainability.The Consortium includes 27 projects led by researchers across a wide range of disciplines, including veterinary medicine, epidemiology, public health, microbiology, genomics, virology, human medicine, law, public policy, economics, sociology, and anthropology.The AMR – One Health Consortium is a collaborative provincial initiative that spans across six universities and three other post-secondary institutions in Alberta, with the University of Calgary as the lead institution. Other collaborators include government agencies and ministries, industry partners and provincial health organizations. The Consortium received $15.569 million in total project funds from various federal, provincial and private sources to be spent over 5 years. $6.315 million was awarded through the Major Innovation Fund (MIF) from the Ministry of Economic Development, Trade and Tourism (EDTT), and $9.254 million was leveraged through matching funds.
Social Link - Linkedin: http://www.linkedin.com/company/amr-one-health-consortium
Employee Count: 1
Keywords: prevention of transmission